Physiology and pathophysiology of IGFBP-1 and IGFBP-2 - consensus and dissent on metabolic control and malignant potential.
Level 5 - mechanism / opinion, no new human data
Narrative review of preclinical and physiological mechanisms with no systematic search methodology or new human clinical data.
PubMed 26522454 · doi:10.1016/j.beem.2015.07.002
What was done
This narrative review synthesizes mechanistic and observational literature on the physiological regulation, metabolic functions, and oncogenic associations of insulin-like growth factor-binding proteins 1 and 2 (IGFBP-1 and IGFBP-2). It focuses on their suppression by growth hormone and insulin, cellular signaling through integrins and the PTEN/PI3K pathway, roles in glucose and fat metabolism, and relationships with breast, ovarian, and prostate cancers.
What was found
The abstract reports qualitative findings and contains no numerical data. Both IGFBP-1 and IGFBP-2 are suppressed by growth hormone and insulin and are reduced in obesity. In mice, IGFBP-2 prevents diet- and age-induced glucose insensitivity and blocks preadipocyte differentiation via two heparin-binding domains absent in IGFBP-1. While IGFBP-1 is not positively associated with reproductive cancer risk, IGFBP-2 correlates with breast, ovarian, and prostate malignancies, potentially acting through PTEN/PI3K pathway modulation.
Why it matters
The review contrasts the metabolic and oncological profiles of IGFBP-1 and IGFBP-2 with the more dominant IGFBP-3, identifying IGFBP-2 as a distinct player in glucose homeostasis and a potential marker or mediator in hormone-related cancers.
Limits
The abstract reports no quantitative effect sizes, confidence intervals, or sample numbers. Much of the functional metabolic evidence is derived from mouse models, and the review does not resolve the exact mechanisms connecting IGFBP-2 to estrogen signaling in humans. As an unsystematic narrative review, it is prone to selection bias.
Cited by
- contradicts As insulin levels decrease, levels of IGF-binding protein 3 (IGFBP-3) increase.